



(11) **EP 1 310 252 A1**

(12) **EUROPEAN PATENT APPLICATION**
 published in accordance with Art. 158(3) EPC

(43) Date of publication:
14.05.2003 Bulletin 2003/20

(21) Application number: **01956934.2**

(22) Date of filing: **17.08.2001**

(51) Int Cl.⁷: **A61K 31/4439**, A61K 31/4184,
 A61K 31/404, A61K 9/08,
 A61K 9/19, A61K 47/02,
 A61K 47/26, A61P 1/04,
 A61P 31/04, A61P 35/00,
 C07D 401/12, C07D 235/28,
 C07D 209/30

(86) International application number:
PCT/JP01/07075

(87) International publication number:
WO 02/015908 (28.02.2002 Gazette 2002/09)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
 Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **18.08.2000 JP 2000248468**

(71) Applicant: **Takeda Chemical Industries, Ltd.**
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:
 • **DOEN, Takayuki**
Suita-shi, Osaka 565-0841 (JP)

- **NAGAO, Masao**
Kashiba-shi, Nara 639-0200 (JP)
- **ASAKAWA, Naoki**
Takatsuki-shi, Osaka 569-1146 (JP)
- **TAKECHI, Nobuyuki**
Osaka-shi, Osaka 532-0022 (JP)

(74) Representative: **Wright, Robert Gordon McRae**
Elkington & Fife,
Prospect House,
8 Pembroke Road
Sevenoaks, Kent TN13 1XR (GB)

(54) **INJECTIONS**

(57) An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a

saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a non-aqueous solvent. The injectable composition is useful as an antiulcer agent.

EP 1 310 252 A1

EP 1 310 252 A1

Description

TECHNICAL FIELD

- 5 [0001] The present invention relates to an injectable composition comprising a benzimidazole compound having an antiulcer action, and a process for producing the same.

BACKGROUND ART

- 10 [0002] As injectable compositions comprising a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound having an antiulcer action, for example, the following injectable compositions have been reported.

15 1) Japanese Patent Application Laid-Open No. 138213/1990 (JP-2-138213A) (EP 0356143) discloses an injectable solution which comprises a benzimidazole compound having an antiulcer action and at least one of ethanol, propylene glycol and polyethylene glycol. The literature also discloses an injectable solution which contains a freeze-dried product of the benzimidazole compound dissolved in a mixture solution of an acidic substance and a polyethylene glycol, and further contains a saccharide such as mannitol and N-methylglucamine. Further, in Example 4 of the literature, 1 g of lansoprazole was dispersed in a distilled water for injection, and 3 ml of 1N-aqueous sodium hydroxide solution was added thereto to dissolve lansoprazole, followed by addition of water to make up to the total of 50 ml. The mixture was subjected to sterile filtration. The resulting filtrate was filled in a portion into vials, followed by lyophilization. The lyophilized powder was dissolved in a dissolving solvent composed of N-methylglucamine, hydrochloric acid and a polyethylene glycol.

20 However, in the injectable solution, the specific liquid composition for dissolution containing an alcohol selected from ethanol, propylene glycol and a polyethylene glycol is required, and an excess of alkali (sodium hydroxide) is employed.

25 2) Japanese Patent Application Laid-Open No. 92853/1994 (JP-6-92853A) (WO94/02141) discloses an injection comprising a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound having an antiulcer activity or a salt thereof and an aqueous solvent without nonaqueous solvent, wherein the pH of the injection is not less than 9.5 and not more than 11.5. In Example of the literature, 1N sodium hydroxide (2.3 ml) is added to 21.3 g of sodium salt of omeprazole (20 g as omeprazole), and a water for injection is added thereto to adjust the pH to 11.5. After filtration for sterilization, this alkaline aqueous solution is charged in vials and is lyophilized, followed by dissolution of the lyophilized product in a physiological saline to give an omeprazole injection.

35 [0003] However, an excess of an alkali (sodium hydroxide) is employed in the injection with the use of an aqueous solvent containing no nonaqueous solvent. Thus, in order to prepare an injection solution with the use of a freeze-dried injection, such complicated operations are required as kneading a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound for wetting and then dissolving the compound. The kneading operation might cause the formation of an exogenous material due to contact of the using instruments with each other. Moreover, owing to the complicated operations, it takes many hours to dissolve, as a result, the high concentration of an alkali aqueous solution is contacted with carbon dioxide in an air to decrease pH of the solution so that the quality of the injection is sometimes deteriorated. Further, there is a possibility that an excess of an alkali causes a pain or dolor and a local irritation by an injection. Therefore, there has been a growing demand for such an injectable composition that there is no need to attach the exclusive dissolving solution for the injectable composition, that the amount of an alkali to be used is as small as possible, and that the kneading operation and the complicated dissolving operation are not required. Moreover, such injectable compositions are considerably needed as preventing pH of the injectable composition from decreasing upon producing and redissolving of the injectable composition, and as maintaining the quality of the injectable composition.

45 [0004] It is, therefore, an object of the present invention to provide an injectable composition having no need to attach the exclusive dissolving solution for the injectable composition and capable of being dissolved in or diluted with a physiological saline or an infusion solution, and a production process of the same.

50 [0005] Another object of the present invention is to provide an injectable composition dissolvable by a simple operation, and a production process of the same.

[0006] Still another object of the present invention is to provide such an excellent injectable composition that pH of the injectable composition does not decline and that a pain (or dolor) or a local irritation is relieved by decreasing the alkali amount to be used, and a production process of the same.

55


DISCLOSURE OF INVENTION

[0007] The inventors of the present invention did intensive research, and finally found that such an injectable com-

EP 1 310 252 A1

position that there is no need to attach the exclusive dissolving solution for the injectable composition and that the kneading operation and the complicated dissolving operation are not required can be obtained by using a 2-[(2-pyridyl)methylsulfinyl]benzimidazole compound having an antiulcer action and a strong alkali in molar ratio of about 1 : 1. The present invention was accomplished based on the above findings.

[0008] That is, the present invention relates to an injectable composition comprising a compound represented by the formula (I) or a salt thereof (hereinafter, sometimes referred to simply as the compound (I)):




wherein a ring A represents a benzene ring which may have a substituent,

R¹ represents a hydrogen atom, an alkyl group which may have a substituent, an acyl group or an alkoxy group, R², R³ and R⁴ are same or different, each representing a hydrogen atom, an alkyl group which may have a substituent, an alkoxy group which may have a substituent, or an amino group which may have a substituent, X represents a nitrogen atom or CH, and Y represents a nitrogen atom or CH

and a strong alkali in a proportion (ratio) of about 1 equivalent of the latter relative to 1 mol of the former.

[0009] In the formula (I), the ring A may represent a benzene ring which may have substituent(s) selected from the group consisting of a halogen atom, a C₁₋₄alkyl group which may be halogenated, a C₁₋₄alkoxy group which may be halogenated and a 5- or 6-membered heterocyclic group; R¹ may represent a hydrogen atom; R² may represent a C₁₋₆alkyl group, a C₁₋₆alkoxy group, a C₁₋₆alkoxy-C₁₋₆alkoxy group or a di-C₁₋₆alkylamino group, in particular a C₁₋₃alkyl group; R³ may represent a hydrogen atom, a C₁₋₆alkoxy-C₁₋₆alkoxy group, or a C₁₋₆alkoxy group which may be halogenated, in particular a C₁₋₃alkoxy group which may be halogenated; R⁴ may represent a hydrogen atom or a C₁₋₆alkyl group (e.g., a C₁₋₃alkyl group), in particular a hydrogen atom; and X and Y each may represent a nitrogen atom.

[0010] Further, the compound represented by the formula (I) may be a compound represented by the following formula (Ia):



wherein R¹ represents a hydrogen atom; R² represents a C₁₋₃alkyl group or a C₁₋₃alkoxy group; R³ represents a C₁₋₃alkoxy group which may be halogenated or may be substituted with a C₁₋₃alkoxy group; R⁴ represents a hydrogen atom or a C₁₋₃alkyl group; and R⁵ represents a hydrogen atom, a C₁₋₃alkoxy group which may be halogenated, or a pyrrolyl group.

[0011] In the formula (Ia), R¹ may represent a hydrogen atom; R² may represent a C₁₋₃alkyl group; R³ may represent a C₁₋₃alkoxy group which may be halogenated; R⁴ may represent a hydrogen atom; and R⁵ may represent a hydrogen atom or a C₁₋₃alkoxy group which may be halogenated.

[0012] The injectable composition of the present invention is usually dissolvable in or dilutable with a solvent (a solvent of which a medium is substantially water) substantially free from a nonaqueous solvent (or a water-soluble organic solvent), and an injectable liquid composition can be easily prepared from the injectable composition.

[0013] The strong alkali may comprise an alkali metal compound (e.g., sodium hydroxide). The equivalent ratio of the strong alkali relative to 1 mol of the compound (I) may be about 0.90 to 1.10.

[0014] Incidentally, the solution of the injectable composition of the present invention may have a pH of about 10.4 to 12.0 in the case where the injectable composition is dissolved with the use of a physiological saline, or a distilled

EP 1 310 252 A1

water for injection in a proportion of 2.5 ml relative to 15 mg of the compound (I). An osmotic pressure ratio of a dissolved solution, obtained by dissolving 15 mg of the compound (I) in 2.5 ml of a physiological saline, relative to the physiological saline may be about 0.3 to 5.

[0015] The injectable composition of the present invention may be a freeze-dried preparation, and such a freeze-dried preparation is dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent.

[0016] The injectable composition of the present invention may further comprise N-methylglucamine. The amount of N-methylglucamine may be about 0.1 to 1 mg relative to 1 mg of the compound (I). The injectable composition may further comprise a saccharide (e.g., a sugar alcohol such as mannitol). The amount of the saccharide may be about 0.1 to 20 mg relative to 1 mg of the compound (I). For example, an injectable composition containing such a component is an injectable composition comprising the compound (I), and being dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent, and may further comprise about 0.1 to 0.8 mg of N-methylglucamine and about 1 to 10 mg of a sugar alcohol relative to 1 mg of the compound (I).

[0017] Further, the injectable composition may, for example, be an injectable composition comprising the compound (I) and being dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent, and further comprising about 4 to 6 mg of N-methylglucamine, about 25 to 35 mg of mannitol and about 1.5 to 1.8 mg of a sodium hydroxide relative to 15 mg of the compound (I), e.g., an injectable composition comprising 30 mg of the compound (I), 3.45 mg of a sodium hydroxide, 10 mg of N-methylglucamine and 60 mg of mannitol, an injectable composition comprising 15 mg of the compound (I), 1.73 mg of a sodium hydroxide, 5 mg of N-methylglucamine and 30 mg of mannitol, and others.

[0018] The injectable composition of the present invention is usually dissolvable in or dilutive with a solvent of which a medium is substantially water, substantially free from a nonaqueous solvent (or a water-soluble organic solvent). Further, the injectable composition of the present invention may be a freeze-dried preparation (a freeze-dried injectable composition), for example, a freeze-dried preparation comprising the compound (I) and an alkali metal hydroxide in a molar ratio of 1 : 0.90 to 1.10, and further comprising about 0.1 to 0.8 mg of N-methylglucamine and about 1 to 10 mg of a sugar alcohol relative to 1 mg of the compound (I). Such a freeze-dried preparation is dissolvable in at least one liquid or solvent selected from waters for injection (a distilled water for injection), infusion solutions including an electrolyte liquid composition (such as a physiological saline), nutrition infusion solutions and others, and an injectable liquid composition can be easily prepared from the injectable composition.

[0019] The injectable composition of the present invention can be produced by dissolving the compound (I) in an aqueous solution of a strong alkali, wherein the concentration of the aqueous solution of the strong alkali is about 0.15 to 0.25 equivalent/L, and the amount of the aqueous solution of the strong alkali is about 1 equivalent relative to 1 mol of the compound (I). The present invention, therefore, includes an injectable composition obtained by the production process. In this process, the aqueous solution of the strong alkali may comprise an aqueous solution of sodium hydroxide.

[0020] Thus, in the present invention, the amount to be used of the strong alkali can be decreased, and the solubility of the compound (I) can be improved. The present invention, therefore, discloses a method for improving a relief of a pain or dolor and local irritation by an injectable composition, which comprises preparing the injectable composition with the use of the compound (I) and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former without a nonaqueous solvent (or a water-soluble organic solvent); and a method for improving the solubility of the freeze-dried preparation in at least one liquid selected from waters for injection, infusion solutions and nutrition infusion solutions, without using a nonaqueous solvent (or a water-soluble organic solvent), which comprises preparing the freeze-dried preparation with the use of the compound (I) and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former.

[0021] The present invention is useful as a method for preventing or treating digestive ulcer, gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer, gastric MALT lymphoma, upper gastrointestinal hemorrhage, ulcer caused by a nonsteroidal anti-inflammatory agent, hyperacidity and ulcer due to postoperative stress, or disease due to *Helicobacter pylori*, which comprises administering the injectable composition to a human being.

[0022] Further, the present invention discloses use of an injectable composition comprising the compound represented by the formula (I) or a salt thereof and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former for preventing or treating digestive ulcer, gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer, gastric MALT lymphoma, upper gastrointestinal hemorrhage, ulcer caused by a nonsteroidal anti-inflammatory agent, hyperacidity and ulcer due to postoperative stress, or disease due to *Helicobacter pylori*. Moreover, the present invention also discloses use of a strong alkali for producing an injectable composition (for example, a freeze-dried preparation or a freeze-dried injectable composition) comprising the compound (I) and the strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former.

[0023] Incidentally, the term "an injectable composition" as used herein means not only a final injectable composition, but also an injectable composition precursor capable of preparing a final injectable composition with the use of a dissolving solvent upon using [for example, a liquid injectable composition (a concentrated or condensed injectable

EP 1 310 252 A1

composition) or a solid injectable composition (such as a freeze-dried injectable composition)]. Moreover, in molar ratio of the compound (I) or a salt thereof and the strong alkali, the expression "about 1 : 1" means an equivalent ratio of the strong alkali relative to 1 mol of the compound (I) or the salt thereof. Further, the phrase "a salt of the compound represented by the formula (I)" means a salt to an acidic group and/or a basic group shown by the substituents, R¹ to R⁵, in the formulae (I) and (Ia).

BRIEF DESCRIPTION OF THE DRAWINGS

[0024]

Fig. 1 is the graph demonstrating the results of Experimental Example 5.

Fig. 2 is the graph demonstrating the results of Experimental Example 6.

DETAILED DESCRIPTION OF THE INVENTION

[0025] The injectable composition of the present invention comprises the compound (I) and a strong alkali in equivalent ratio of about 1 : 1. That is, the injectable composition comprises about 1 equivalent of the strong alkali relative to 1 mol of the compound (I).

[0026] In the compound (I), examples of the "substituent" of the "benzene ring which may have a substituent" shown by the ring A include, for example, a halogen atom, a cyano group, a nitro group, an alkyl group which may have a substituent, a hydroxyl group, an alkoxy group which may have a substituent, an aryl group, an aryloxy group, a carboxyl group, an acyl group, an acyloxy group, and a 5- to 10-membered heterocyclic ring. The benzene ring may be substituted with about 1 to 3 substituents. When substituted with two or more substituents, each of substituents may be same or different. Among these substituents, a halogen atom, an alkyl group which may have a substituent, and an alkoxy group which may have a substituent are preferred.

[0027] As the halogen atom, there may be mentioned fluorine, chlorine, bromine atoms and the like. In Particular, a fluorine atom is preferred.

[0028] The "alkyl group" as the "alkyl group which may have a substituent" includes, for example, a C₁₋₇alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, and heptyl groups). The "substituent" as the "alkyl group which may have a substituent" includes, for example, a halogen atom, a hydroxyl group, a C₁₋₆alkoxy group (e.g., methoxy, ethoxy, propoxy, and butoxy groups), a C₁₋₆alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl groups), and a carbamoyl group. The alkyl group may be substituted with about 1 to 3 substituents. When substituted with two or more substituents, each of substituents may be same or different.

[0029] The "alkoxy group" as the "alkoxy group which may have a substituent" includes, for example, a C₁₋₆alkoxy group (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and pentoxy groups). The "substituent" as the "alkoxy group which may have a substituent" includes the groups similar to those exemplified in the item of the "substituent" as the "alkyl group which may have a substituent", and the number to be substituted with the substituent is also same as that exemplified in the item of the "substituent" as the "alkyl group which may have a substituent".

[0030] As the "aryl group", there may be mentioned, for example, a C₆₋₁₄aryl group (e.g., phenyl, 1-naphthyl, 2-naphthyl, biphenyl, and 2-anthryl groups).

[0031] As the "aryloxy group", there may be mentioned, for example, a C₆₋₁₄aryloxy group (e.g., phenyloxy, 1-naphthyloxy, and 2-naphthyloxy groups).

[0032] Examples of the "acyl group" include formyl, alkylcarbonyl, alkoxy carbonyl, carbamoyl, alkylcarbamoyl, alkylsulfinyl, and alkylsulfonyl groups, etc.

[0033] The "alkylcarbonyl group" includes a C₁₋₆alkyl-carbonyl group (e.g., acetyl and propionyl groups).

[0034] The "alkoxy carbonyl group" includes a C₁₋₆alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and butoxycarbonyl groups).

[0035] As examples of the "alkylcarbamoyl group", there may be mentioned an N-C₁₋₆alkyl-carbamoyl group (e.g., methylcarbamoyl and ethylcarbamoyl groups), an N,N-diC₁₋₆alkylcarbamoyl group (e.g., N,N-dimethylcarbamoyl, and N,N-diethylcarbamoyl groups).

[0036] Examples of the "alkylsulfinyl group" include, for example, a C₁₋₇alkylsulfinyl group (e.g., methylsulfinyl, ethylsulfinyl, propylsulfinyl, and isopropylsulfinyl groups).

[0037] Examples of the "alkylsulfonyl group" include, for example, a C₁₋₇alkylsulfonyl group (e.g., methylsulfonyl, ethylsulfonyl, propylsulfonyl, and isopropylsulfonyl groups).

[0038] The "acyloxy group" includes, for example, an alkylcarbonyloxy group, an alkoxy carbonyloxy group, a carbamoyloxy group, an alkylcarbamoyloxy group, an alkylsulfinyloxy group, and an alkylsulfonyloxy group.

[0039] As examples of the "alkylcarbonyloxy group", there may be mentioned a C₁₋₆alkyl-carbonyloxy group (e.g.,

EP 1 310 252 A1

acetyloxy and propionyloxy groups).

[0040] Examples of the "alkoxycarbonyloxy group" include, for example, a C₁₋₆alkoxy-carbonyloxy group (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, and butoxycarbonyloxy groups).

[0041] The "alkylcarbamoyloxy group" includes a C₁₋₆alkyl-carbamoyloxy group (e.g., methylcarbamoyloxy and ethylcarbamoyloxy groups).


[0042] As examples of the "alkylsulfinyloxy group", there may be mentioned, for example, a C₁₋₇alkylsulfinyloxy group (e.g., methylsulfinyloxy, ethylsulfinyloxy, propylsulfinyloxy, and isopropylsulfinyloxy groups).

[0043] Examples of the "alkylsulfonyloxy group" include a C₁₋₇alkylsulfonyloxy group (e.g., methylsulfonyloxy, ethylsulfonyloxy, propylsulfonyloxy, and isopropylsulfonyloxy groups).


[0044] The "5- to 10-membered heterocyclic group" includes, for example, a 5- to 10-membered (preferably 5- or 6-membered) heterocyclic group having 1 or more (e.g., 1 to 3) hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom other than carbon atom. The typical examples include 2- or 3-thienyl group, 2-, 3- or 4-pyridyl group, 2- or 3-furyl group, 1-, 2- or 3-pyrrolyl group, 2-, 3-, 4-, 5- or 8-quinolyl group, 1-, 3-, 4- or 5-isoquinolyl group, 1-, 2- or 3-indolyl group and the like. Among them, the preferred heterocyclic group includes a 5- or 6-membered heterocyclic group such as 1-, 2- or 3-pyrrolyl group.

[0045] It is preferred that the ring A is a benzene ring which may have 1 or 2 substituents selected from a halogen atom, a C₁₋₄alkyl group which may be halogenated, a C₁₋₄alkoxy group which may be halogenated, and a 5- or 6-membered heterocyclic group.

[0046] Preferred as a group represented by the following formula:



wherein each letter has the same meaning as mentioned above, is a group represented by the following formula:



wherein R⁵ represents a hydrogen atom, a C₁₋₄alkyl group which may be halogenated, an alkoxy group which may be halogenated, or a 5- or 6-membered heterocyclic group; R¹ has the same meaning as mentioned above.

[0047] R⁵ is preferably (1) a hydrogen atom, (2) a C₁₋₃alkoxy group which may be halogenated, or (3) a pyrrolyl group (e.g., 1-, 2- or 3-pyrrolyl group). R⁵ is usually a hydrogen atom, or a C₁₋₃alkoxy group which may be halogenated.

[0048] As the "aralkyl group" in the "aralkyl group which may have a substituent" shown by R¹, there may be mentioned, for example, a C₇₋₁₆aralkyl group (e.g., a C₆₋₁₀aryl-C₁₋₆alkyl group such as benzyl and phenethyl groups). As the "substituent" in the "aralkyl group which may have a substituent", there may be mentioned, for example, the groups similar to those exemplified in the item of the "substituent" as the "alkyl group which may have a substituent", and the number to be substituted with the substituent is about 1 to 4. When the number of the substituent is not less than 2, the substituents are same or different from each other.

[0049] The "acyl group" shown by R¹ includes, for example, the "acyl group" mentioned as the substituent of the ring A.

[0050] The "acyloxy group" shown by R¹ includes, for example, the "acyloxy group" mentioned as the substituent of the ring A.

[0051] The preferred R¹ is a hydrogen atom.

[0052] The "alkyl group which may have a substituent" shown by R², R³ or R⁴ includes the "alkyl group which may have a substituent" mentioned as the substituent of the ring A.

[0053] The "alkoxy group which may have a substituent" shown by R², R³ or R⁴ includes the "alkoxy group which

EP 1 310 252 A1

may have a substituent" mentioned as the substituent of the ring A.

[0054] The "amino group which may have a substituent" shown by R², R³ or R⁴ includes, for example, an amino group, a mono-C₁₋₆alkylamino group (e.g., methylamino and ethylamino groups), a mono-C₆₋₁₄aryl amino group (e.g., phenylamino, 1-naphthylamino, and 2-naphthylamino groups), a di-C₁₋₆alkylamino group (e.g., dimethylamino and diethylamino groups), a di-C₆₋₁₄aryl amino group (e.g., diphenylamino group).

[0055] The preferred R² is a C₁₋₆alkyl group, a C₁₋₆alkoxy group, a C₁₋₆alkoxy-C₁₋₆alkoxy group, and a di-C₁₋₆alkylamino group. The further preferred R² is a C₁₋₃alkyl group or a C₁₋₃alkoxy group.

[0056] The preferred R³ is a hydrogen atom, a C₁₋₆alkoxy-C₁₋₆alkoxy group, or a C₁₋₆alkoxy group which may be halogenated. The further preferred R³ is a C₁₋₃alkoxy group which may be halogenated or may be substituted with a C₁₋₃alkoxy group.

[0057] The preferred R⁴ is a hydrogen atom or a C₁₋₆alkyl group. The further preferred R⁴ is a hydrogen atom or a C₁₋₃alkyl group (in particular, a hydrogen atom).

[0058] The preferred X is a nitrogen atom.

[0059] The preferred Y is a nitrogen atom.

[0060] The typical examples of the compound (I) includes the following compounds:

2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole,
2-[[[3,5-dimethyl-4-methoxy-2-pyridinyl]methyl]sulfinyl]-5-methoxy-1H-benzimidazole,
a sodium salt of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole,
5-difluoromethoxy-2-[[[3,4-dimethoxy-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, and the like.

[0061] Among them, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole is preferred.

[0062] Incidentally, the compound (I) may be a racemic compound, and may be an optically active substance such as a R-isomer or a S-isomer. For example, the compound (I) may be an optically active substance such as (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole.

[0063] The salt of the compound represented by the formula (I) preferably includes a pharmaceutically acceptable salt, for example, a salt with an inorganic base, a salt with an organic base, a salt with a basic amino acid and the like.

[0064] As the preferred examples of the salt with an inorganic base, there may be mentioned, for example, an alkali metal salt such as a sodium salt and a potassium salt; an alkaline earth metal salt such as a calcium salt and a magnesium salt; and an ammonium salt.

[0065] The preferred examples of the salt with an organic base include, for example, a salt with an alkylamine (e.g., trimethylamine, triethylamine), a heterocyclic amine (e.g., pyridine, picoline), an alkanolamine (e.g., ethanolamine, diethanolamine, triethanolamine), dicyclohexylamine, N,N'-dibenzylethylenediamine or the like.

[0066] The preferred examples of the salt with a basic amino acid include, for example, a salt with arginine, lysine, ornithine or the like.

[0067] Among these salts, the alkali metal salt or the alkaline earth metal salt is preferred. In particular, the sodium salt is preferred.

[0068] The compound (I) can be prepared by per se known methods, for example, the methods described in Japanese Patent Application Laid-Open No. 50978/1986 (JP-61-50978A), USP 4,628,098, Japanese Patent Application Laid-Open No. 195068/1998 (JP-10-195068A), WO 98/21201 or methods based on these methods. Incidentally, an optically active compound (I) can be obtained by an optical resolution method (e.g., a fractional recrystallization method, a chiral column method, a diastereomer method, a method with a microorganism or an enzyme), an asymmetric oxidation method.

[0069] It is sufficient that the "strong alkali" has a strong basicity, and the "strong alkali" may be a base such as a hydroxide, or may be in the form of a salt such as carbonate and acetate. As the base, there may be mentioned a compound having a large degree of electrolytic dissociation in an aqueous solution, for example, a compound having a degree of electrolytic dissociation of not less than about 0.5. Moreover, although most of salts are strong electrolytes, a basic substance having pH of about not less than 11, particularly about not less than 11.5 in an aqueous solution is preferred. As such strong alkalis, there may be mentioned, for example, an alkali metal compound (e.g., an alkali metal hydroxide such as sodium hydroxide and potassium hydroxide, an alkaline earth metal carbonate such as sodium carbonate and potassium carbonate), a strong basic substance such as arginine. These strong alkalis can be used singly or in combination. The preferred strong alkali includes the alkali metal compound, for example, the alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide) in particular, sodium hydroxide.

[0070] The content of the "strong alkali" is about 1 equivalent, preferably about 0.80 to 1.20 equivalents, more preferably about 0.90 to 1.10 (e.g., about 0.95 to 1.08) equivalents, and particularly about 0.97 to 1.08 (e.g., about 1.0 to 1.08) equivalents relative to 1 mol of the compound (I).

[0071] According to the present invention, the amount of the strong alkali can be decreased, and the solubility of the

EP 1 310 252 A1

injectable composition can be improved with being substantially free from using a nonaqueous solvent (or a water-soluble organic solvent). Therefore, the present invention also discloses use of a strong alkali for producing the above injectable composition.

[0072] The injectable composition of the present invention may further comprise N-methylglucamine. The content of the "N-methylglucamine" is about 0.1 to 1 mg, preferably about 0.1 to 0.8 mg, more preferably about 0.2 to 0.6 mg and particularly about 0.3 to 0.5 mg (e.g., about 0.3 to 0.4 mg) relative to 1 mg of the compound (I).

[0073] Addition of N-methylglucamine enables to prevent pH from declining owing to buffer action of N-methylglucamine and enables to inhibit deterioration of the quality of a preparation due to precipitation of impurities. Further, by incorporating N-methylglucamine, such a high pH can be maintained as about 9 to 11, and further, as about 8 to 11 can be retained depending on the concentration.

[0074] The "injectable composition" of the present invention may further comprise a saccharide (a sugar). As the "saccharide", there may be mentioned, for example, a monosaccharide (e.g., glucose, galactose, ribose, xylose, mannose, maltotriose, maltotetraose), a disaccharide (e.g., sucrose, lactose, cellobiose, maltose), a trisaccharide (e.g., raffinose), a sugar alcohol (e.g., sorbitol, inositol, mannitol), a polysaccharide (e.g., dextran, chondroitin sulfate, hyaluronic acid, dextrin sulfate) and a salt thereof (e.g., sodium salt of chondroitin sulfate, sodium salt of hyaluronic acid), a cyclic saccharide (e.g., cyclodextrin, branched cyclodextrin). Of these saccharides, a sugar alcohol is preferred. Mannitol is particularly preferred.

[0075] The content of the "saccharide" is about 0.1 to 20 mg, preferably about 0.5 to 10 mg (e.g., about 1 to 10 mg), more preferably about 1 to 5 mg (e.g., about 1 to 3.3 mg) relative to 1 mg of the compound (I).

[0076] The injectable composition of the present invention may further comprise an additive.

[0077] As the "additive", there may be mentioned, for example, a water-soluble inorganic acid (e.g., hydrochloric acid, sulfuric acid, carbonic acid, phosphoric acid), an alkali metal salt of a water-soluble inorganic acid (e.g., sodium chloride, potassium chloride, sodium sulfate, potassium sulfate), an alkaline earth metal salt of a water-soluble inorganic acid (e.g., calcium chloride, magnesium chloride), a water-soluble organic acid (e.g., citric acid, tartaric acid, lactic acid, succinic acid, malic acid, acetic acid, oxalic acid, benzoic acid, tannic acid, gluconic acid, fumaric acid, sorbic acid, erysorbic acid, mesylic acid, mefenamic acid), an alkali metal salt of a water-soluble organic acid (e.g., sodium citrate, sodium tartrate), an alkaline earth metal salt of a water-soluble organic acid (e.g., calcium citrate, calcium lactate, magnesium gluconate), a neutral amino acid (e.g., glycine, alanine), an acidic amino acid (e.g., aspartic acid, glutamic acid), a salt of an acidic amino acid (e.g., sodium aspartate, potassium glutamate), a salt of a basic amino acid (e.g., lysine hydrochloride, arginine hydrochloride).

[0078] Moreover, if necessary, in the "injectable composition" of the present invention may be employed a buffer (e.g., sodium dihydrogenphosphate, disodium hydrogenphosphate), an isotonicizing agent (e.g., glucose, sodium chloride), a stabilizer (e.g., sodium hydrogensulfite), a soothing agent (e.g., glucose, benzyl alcohol, mepivacaine hydrochloride, xylocaine hydrochloride, procaine hydrochloride, carbocaine hydrochloride), a preservative (e.g., p-oxybenzoate such as methyl p-oxybenzoate and propyl p-oxybenzoate, thymelosal, chlorobutanol, benzyl alcohol).

[0079] The typical examples of the injectable composition of the present invention include an injectable composition comprising the compound (I), a strong alkali (e.g., an alkali metal hydroxide), N-methylglucamine and a saccharide. The preferred injectable composition includes an injectable composition comprising the compound (I), sodium hydroxide, N-methylglucamine and mannitol. In such an injectable composition, the amount of each component may be about 4 to 6 mg of N-methylglucamine, about 25 to 35 mg of a sugar alcohol (e.g., mannitol) and about 1.5 to 1.8 mg of sodium hydroxide relative to 15 mg of the compound (I). More specifically, the injectable composition may be an injectable composition comprising 30 mg of the compound (I), 3.45 mg of sodium hydroxide, 10 mg of N-methylglucamine and 60 mg of mannitol (hereinafter, sometimes referred to simply as the preparation (I)), or an injectable composition comprising 15 mg of the compound (I), 1.73 mg of sodium hydroxide, 5 mg of N-methylglucamine and 30 mg of mannitol (hereinafter, sometimes referred to simply as the preparation (II)).

[0080] The injectable composition of the present invention may be in the form of a liquid (e.g., in the form of an aqueous injection solution), or may be in the form of a semi-solid (e.g., concentrated aqueous injectable composition) or a solid. The preferred injectable composition of the present invention is a freeze-dried preparation (freeze-dried injectable composition). The injectable composition of the present invention also includes an injectable composition dissolved in or diluted with a dissolving liquid composition or a diluting liquid composition upon using.

[0081] The injectable composition of the present invention (in particular, a freeze-dried preparation) can be dissolved in or diluted with an aqueous dissolving liquid composition or diluting liquid composition such as a dissolving liquid composition or a diluting liquid composition substantially free from a nonaqueous solvent (e.g., a water-soluble organic solvent such as propylene glycol and polyethylene glycol), for example, a water for injection such as a distilled water for injection, an infusion solution (e.g., an electrolyte liquid composition such as a physiological saline) so that the injectable composition can be easily prepared. Therefore, the injectable composition of the present invention is, usually, substantially free from a nonaqueous solvent (e.g., a water-soluble organic solvent such as propylene glycol and polyethylene glycol). Moreover, in an aqueous injectable composition (injection solution), the solubility of the compound

EP 1 310 252 A1

(I) is not deteriorated even when a solvent is substantially water (e.g., a distilled water). Further, since the amount to be used of the strong alkali can be decreased without a nonaqueous solvent, a pain or dolor and a local irritation of the injectable composition can be relieved and decline of pH of the injectable composition can be inhibited. Therefore, the present invention also discloses a method for improving a relief of a pain or dolor and local irritation by an injectable composition and a method for improving a solubility of the injectable composition (especially, a freeze-dried preparation).

[0082] The injectable composition of the present invention has a pH of about 10.4 to 12.0, preferably about 10.5 to 11.5 and more preferably about 10.6 to 11.3 in the case where 15 mg of the compound (I) is dissolved in 2.5 ml of a physiological saline, or a distilled water for injection. In other words, in a solution obtained by redissolving the preparation (I) in 5 ml of a physiological saline or a water for injection and a solution obtained by redissolving the preparation (II) in 2.5 ml of a physiological saline or a water for injection, each solution usually has the above pH. When the preparation (I) is further diluted with up to about 1 L of a physiological saline, pH of the preparation (I) is about 9 to 11.

[0083] Incidentally, an aqueous solution of N-methylglucamine has a sufficient buffer activity at pH of about 9 to 11 so that the decline of pH of a solution containing the compound (I) can be inhibited and the deterioration of the quality can be suppressed upon producing an injectable composition comprising the compound (I) and redissolving the injectable composition.

[0084] Further, in the case where 15 mg of the compound (I) is dissolved in 2.5 ml of a physiological saline, an osmotic pressure ratio of the resultant dissolved solution relative to the physiological saline is, for example, about 0.3 to 5, preferably about 0.5 to 3, and more preferably about 1 to 2. In other words, in a solution obtained by dissolving the preparation (I) in 5 mL of a physiological saline and a solution obtained by dissolving the preparation (II) in 2.5 mL of a physiological saline, each solution usually has the above osmotic pressure ratio (when an osmotic pressure of 0.9% physiological saline is assumed to be 1).

[0085] The injectable composition of the present invention can be produced by dissolving the compound (I) in a strong alkali aqueous solution (e.g., an aqueous solution of sodium hydroxide) and filling the solution into a vial or an ampoule, and if necessary, lyophilizing the solution. When N-methylglucamine, a saccharide and an additive are added, an injectable composition can be obtained by dissolving the compound (I), N-methylglucamine, a saccharide and an additive etc. in a strong alkali aqueous solution (e.g., an aqueous solution of sodium hydroxide) and filling the solution into a vial or an ampoule, and if necessary, lyophilizing the solution. In particular, an injectable composition can be produced by dissolving the compound (I) into a strong alkali aqueous solution having a specific concentration (e.g., an aqueous solution of sodium hydroxide) in a proportion of about 1 equivalent of the strong alkali (e.g., sodium hydroxide) relative to 1 mol of the compound (I).

[0086] The concentration of the "strong alkali aqueous solution" is about 0.15 to 0.25 equivalent/L, preferably about 0.17 to 0.23 equivalent/L and in particular about 0.18 to 0.22 equivalent/L (e.g., about 0.19 to 0.21 mol/L). In other words, for example, in the case where sodium hydroxide is employed as the strong alkali, the concentration of the "sodium hydroxide aqueous solution" is about 0.15 to 0.25 mol/L, and preferably about 0.18 to 0.22 mol/L. In the case where the concentration of the sodium hydroxide is less than 0.1 mol/L, the enough solubility cannot be obtained and the compound (I) cannot be dissolved completely so that the resultant dissolved solution becomes white-turbid. In the case where the concentration is more than 0.25 mol/L, the sufficient kneading operation followed by diluting with a water for injection are required for dissolving the compound (I) so that very complicated operations are needed. Incidentally, in the case where a strong alkali other than sodium hydroxide is employed as the strong alkali, the injectable composition of the present invention can be also produced according to the above method.

[0087] The "dissolving" of the compound (I) in a strong alkali aqueous solution may be carried out by per se known methods.

[0088] The "freeze-drying (lyophilization)" may be carried out by per se known methods, and is desirably conducted by freezing a solution at a temperature of not higher than -25°C, and drying the resultant with elevating the shelf temperature to 25 to 40°C while retaining a vacuum degree of a drying oven at a pressure of not more than about 13.3 Pa, in general.

[0089] As the "vial", one made of a glass capable of employing for an injectable composition is preferred. The preferred "vial" is USP TYPE I, II, III or the like, particularly TYPE I. Moreover, such a glass vial that decreases the amount to be eluted of an alkali more than usual, or a plastic vial such as a vial made from a cyclic polyolefin [e.g., CZ vial manufactured by Daikyo Seiko, Ltd.] is also employed. The configuration and the size of the vial are not particularly limited. The capacity of the vial is preferably not more than 100 mL, more preferably not more than 40 mL, and particularly not more than 20 mL. The typical examples of vials include, for example, 17P vial, 9P vial, 5P vial, and 3.5P vial.

[0090] As the "ampoule", one made of a glass capable of employing for an injectable composition is preferred. The configuration and the size of the ampoule are not particularly limited. The capacity of the ampoule is preferably not more than 30 mL, more preferably not more than 20 mL, and particularly not more than 10 mL. The typical examples of ampoule include, for example, 10P ampoule, 5P ampoule, and 3P ampoule.

[0091] Upon redissolving the injectable composition of the present invention, in the case where it takes many hours

EP 1 310 252 A1

to become transparent due to vigorous foaming of the contents, the redissolving time can be reduced by using a vial or an ampoule coated with a silicone. As the silicone to be used in coating, there may be mentioned, a silicone oil such as a poly(dimethylsiloxane), a poly(methylhydrogensiloxane); a varnish silicone such as a methyl varnish silicone and a methyl phenyl varnish silicone. As one example of the preferred silicone, there may be mentioned KM-740 [manufactured by Shin-Etsu Chemical Co., Ltd.].

[0092] In the case where the injectable composition of the present invention is an aqueous injectable composition, a predetermined amount of the injectable composition is pulled out by means of an injection syringe from a vial or an ampoule to be used. In the case where the injectable composition of the present invention is a freeze-dried preparation, the preparation is utilized with redissolving upon using.

[0093] As to the "solvent for redissolving", there is no need to employ a solution containing such a nonaqueous solvent as might exhibit a toxicity when used in high concentration (e.g., polyethylene glycol). Examples of the solvent for redissolving include, for example, a water for injection (a distilled water for injection), an infusion solution [an electrolyte liquid composition (e.g., a physiological saline, a Ringer's solution), a nutrition infusion solution (a carbohydrate solution (e.g., a glucose solution such as 5% (w/v) glucose solution), an injectable liquid composition of a protein amino acid, an injectable liquid composition of a vitamin), a blood substitute combined an electrolyte liquid composition or a nutrition infusion solution (e.g., a carbohydrate solution), a fat emulsion preparation emulsifying fat], and a mixed solvent of two kinds or more thereof. To the solvent may be optionally added a pH-adjusting agent (e.g., an acidic substance, a weak-alkaline substance). Incidentally, the injectable composition of the present invention may be redissolved in an organic solvent such as ethanol, propylene glycol and polyethylene glycol, and after dissolving in the organic solvent, the injectable composition may be further diluted with the above "solvent for redissolving" to be used.

[0094] The "electrolyte liquid composition" is a liquid composition obtained by dissolving an electrolyte in a water for injection, and includes, for example, a solution comprising one or more kinds of sodium chloride, potassium chloride, calcium chloride, sodium lactate, sodium dihydrogenphosphate, magnesium carbonate and the like, a Ringer's solution of lactic acid, a Ringer's solution of acetic acid. The preferred electrolyte liquid composition includes a solution containing sodium chloride, in particular, a physiological saline [0.9% (w/v) sodium chloride solution].

[0095] The "carbohydrate solution (liquid composition)" is a liquid composition obtained by dissolving a saccharide in a water for injection, and includes, for example, a solution containing one or more kinds of glucose, fructose, sorbitol, mannitol, dextran and the like. The preferred saccharide solution includes 5 to 70% (w/v) glucose solution, especially, 5% (w/v) glucose solution and 10% (w/v) glucose solution.

[0096] The "injectable liquid composition of a protein amino acid" is a liquid composition obtained by dissolving an amino acid in a water for injection, and includes, for example, a solution containing one or more kinds of glycine, aspartic acid, lysine and the like.

[0097] The "injectable liquid composition of a vitamin" is a liquid composition obtained by dissolving a vitamin in a water for injection, and includes, for example, a solution containing one or more kinds of vitamin B1, vitamin C and the like.

[0098] The preferred "a solvent for redissolving" includes a water for injection, a physiological saline, and a glucose solution (e.g., 5% (w/v) glucose solution).

[0099] According to the injectable composition of the present invention, the solubility of the compound (I) does not decline, and there is no need to employ such a nonaqueous solvent as has a possibility of toxicity when used in high concentration (e.g., polyethylene glycol). Therefore, there is no need to attach a dissolving solution containing a non-aqueous solvent to the injectable composition, and the injectable composition is capable of being dissolved in or diluted with various infusion solutions upon being used at a hospital. Moreover, the injectable composition of the present invention has an excellent stability.

[0100] Further, according to a production process of the injectable composition of the present invention, the injectable composition can be produced with a minimum amount of sodium hydroxide to be required, and such an injectable composition that a pain or dolor and a local irritation are relieved can be obtained. Furthermore, since a freeze-dried preparation is simply produced, pH does not decrease due to contact with carbon dioxide in an air, and the high quality injectable composition can be obtained. Moreover, when N-methylglucamine is added, the decline of pH upon producing the injectable composition or after redissolving the injectable composition can be inhibited, and the higher quality injectable composition prevented from deteriorating a quality thereof can be provided.

[0101] The compound (I) has an excellent antiulcer action, gastric acid secretion-inhibiting action, mucosa-protecting action, anti-Helicobacter pylori action, etc., and has low toxicity.

[0102] The injectable composition of the present invention is useful in mammals (e.g., human beings, non-humans such as monkeys, sheep, bovines, horses, dogs, cats, rabbits, rats, mice, etc.) for the treatment and prevention of digestive (peptic) ulcer (e.g., gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, etc.), gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer (inclusive of gastric ulcer accompanied with enhanced production of interleukin-1 β due to genetic polymorphism of interleukin-1), gastric MALT lymphoma; disease due to Helicobacter pylori; upper gastrointestinal hemorrhage due to digestive ulcer (peptic ulcer), acute stress ulcer and

EP 1 310 252 A1

hemorrhagic gastritis; upper gastrointestinal hemorrhage due to invasive stress (stress from major surgery necessitating intensive management after surgery, and from cerebral vascular disorder, head trauma, multiple organ failure and extensive burn necessitating intensive treatment); and ulcer caused by a nonsteroidal anti-inflammatory agent. Further, the injectable composition of the present invention is also useful for *Helicobacter pylori* eradication; suppression of the above-mentioned upper gastrointestinal hemorrhage; treatment and prevention of hyperacidity and ulcer due to postoperative stress; pre-anesthetic administration etc. The injectable composition of the present invention can be administered non-orally (e.g., drip administration, intravenous administration, intramuscular administration, hypodermic administration) for treating or preventing these diseases.

[0103] The compound (I) as an active ingredient in the injectable composition of the present invention may be used in combination with other active ingredients (e.g., 1 to 3 other active ingredients).

[0104] The "other active ingredients" include, for example, substances having anti-*Helicobacter pylori* action, imidazole-series compounds, bismuth salts, quinolone-series compounds, and so forth. Of these substances, preferred are anti-*Helicobacter pylori* active substances, imidazole-series compounds etc. The "anti-*Helicobacter pylori* active substances" include, for example, antibiotic penicillins (e.g., amoxicillin, benzylpenicillin, piperacillin, mecillinam, etc.), antibiotic cefems (e.g., cefixime, cefaclor, etc.), antibiotic macrolides (e.g., antibiotic erythromycins such as erythromycin, clarithromycin etc.), antibiotic tetracyclines (e.g., tetracycline, minocycline, streptomycin, etc.), antibiotic aminoglycosides (e.g., gentamicin, amikacin, etc.), imipenem, and so forth. Of these substances, preferred are antibiotic penicillins, antibiotic macrolides etc. The "imidazole-series compounds" include, for example, metronidazole, miconazole, etc. The "bismuth salts" include, for example, bismuth acetate, bismuth citrate, etc. The "quinolone-series compounds" include, for example, ofloxacin, ciprofloxacin, etc. In particular, it is preferred for *Helicobacter pylori* eradication that the injectable composition of the present invention is used in combination with antibiotic penicillins (e.g., amoxicillin) and/or antibiotic erythromycins (e.g., clarithromycin).

[0105] The dose per day of the injectable composition varies depending on degree of symptom; age, distinction of sex and weight of a subject of administration; time and interval of administration; species of active ingredients, etc., and is not particularly limited. Its dose per day is about 0.1 to 2 mg/kg weight, and preferably about 0.2 to 1 mg/kg weight, based on the active ingredient (the compound (I)), for example, when non-orally administered as a digestive antiulcer agent to an adult human (60 kg). The injectable composition of the present invention is administered once a day or in 2 to 3 divided portions per day. The concentration of the compound (I) in the injectable composition to be administered is about 0.001 to 40 mg/mL, preferably about 0.01 to 30 mg/mL, and particularly preferably about 0.03 to 10 mg/mL.

INDUSTRIAL APPLICABILITY

[0106] According to the injectable composition of the present invention, the solubility of the compound (I) does not decline, and there is no need to employ such a nonaqueous solvent as has a possibility of showing a toxicity when used in high concentration (e.g., polyethylene glycol). Therefore, there is no need to attach a dissolving solution containing a nonaqueous solvent to the injectable composition, and the injectable composition is capable of being dissolved in or diluted with various infusion solutions upon being used at a hospital. Moreover, the injectable composition of the present invention has an excellent stability.

[0107] Further, according to a production process of the injectable composition of the present invention, the injectable composition can be produced with a minimum amount of sodium hydroxide to be required, and such injectable composition that a pain or dolor and a local irritation are relieved can be obtained. Furthermore, since a freeze-dried preparation can be simply produced, decline of pH due to contact with carbon dioxide in an air is not caused, and the high-quality injectable composition can be obtained.

[0108] Moreover, according to the present invention, the decline of pH upon producing the injectable composition or redissolving the injectable composition for using can be prevented, and the quality of the injectable composition can be prevented from being deteriorated.

EXAMPLES

[0109] The following examples are intended to describe this invention in further detail and should by no means be interpreted as defining the scope of the invention.

Example 1

[0110] 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (hereinafter, referred to briefly as compound A) (0.509 g) was quickly dissolved in the equivalent amount (in molar ratio) of a sodium hydroxide aqueous solution (0.2 mol/L, 7.32 mL), and a water for injection was added thereto to adjust the total volume to 33.95

EP 1 310 252 A1

mL. The resultant solutions (1 mL and 2 mL) were filled into vials to prepare injectable compositions of formulations 1 and 2 in Table 1. Each preparation is transparent and colorless.

Table 1

	Formulation 1	Formulation 2
Compound A	15 mg	30 mg
0.2 mol/L sodium hydroxide	0.216 mL	0.431 mL
Water for injection	total 1 mL	total 2 mL

Example 2

[0111] In accordance with the formulation of preparation solution in Table 2, the compound A was dissolved in the equivalent amount (in molar ratio) of a sodium hydroxide aqueous solution (0.2 mol/L), and then mannitol, N-methylglucamine and a water for injection were added thereto to dissolve followed by sterile filtration with a filter (0.22 μ m) made from Durapola (manufactured by Nihon Millipore Ltd.) to prepare a preparation solution for injectable composition A.

[0112] The resultant preparation solutions for injectable composition A (1 mL and 2 mL) were filled into 5P vial and 9P vial, respectively, to produce aqueous injectable compositions of formulations 1 and 2 in Table 3.

[0113] The compound A could be quickly dissolved in the equivalent amount (in molar ratio) of a sodium hydroxide aqueous solution (0.2 mol/L), and the resultant solution was transparent and colorless.

Table 2

	Formulation of preparation solution
Compound A	9.0 g
Mannitol	18.0 g
N-methylglucamine	3.0 g
0.2 mol/L sodium hydroxide aqueous solution	129.4 mL
Compound A : Sodium hydroxide (molar ratio)	1 : 1.06
Water for injection	total 600 mL

Table 3

	Formulation 1	Formulation 2
Compound A	15 mg	30 mg
N-methylglucamine	5 mg	10 mg
Mannitol	30 mg	60 mg
0.2 mol/L sodium hydroxide	0.216 mL	0.431 mL
Water for injection	total 1mL	total 2mL

Example 3

[0114] The preparation solutions for injectable composition A obtained in Example 2 (1 mL and 2 mL) were filled into 5P vial and 17P vial, respectively, and frozen to -40°C followed by lyophilization by elevating shelf temperatures to 0°C and 30°C with keeping a degree of vacuum in a drying oven at 13.3 Pa to produce freeze-dried injectable compositions of formulations 3 and 4 in Table 4.

Table 4

	Formulation 3	Formulation 4
Compound A	15 mg	30 mg

EP 1 310 252 A1

Table 4 (continued)

	Formulation 3	Formulation 4
N-methylglucamine	5 mg	10 mg
Mannitol	30 mg	60 mg
Sodium hydroxide	1.73 mg	3.45 mg

Experimental Example 1

[0115] In accordance with the formulations 1 and 2 in Table 5, the compound A was dissolved in 0.2 mol/L sodium hydroxide aqueous solution, and then mannitol, N-methylglucamine and a water for injection were added thereto to dissolve followed by sterile filtration with a filter (0.22 μ m) made from Durapola (manufactured by Nihon Millipore Ltd.). The resultant preparation solutions (1 mL and 2 mL) were filled into 9P vial and 17P vial, respectively, followed by lyophilization by the method similar to that of Example 3 to produce freeze-dried injectable compositions of formulations 1 and 2. The qualities of the resultant freeze-dried injectable compositions of formulations 1 and 2 are shown in Table 6.

[0116] As apparent from Table 6, the qualities of the injectable compositions are sufficient not only in the case where the freeze-dried injectable composition of the formulation 1 is redissolved in a physiological saline (2.5 mL) but also in the case where the freeze-dried injectable composition of the formulation 2 is redissolved in a physiological saline (5 mL).

Table 5

	Formulation 1	Formulation 2
Compound A	15 mg	30 mg
N-methylglucamine	5 mg	10 mg
Mannitol	30 mg	60 mg
0.2 mol/L Sodium hydroxide	0.216 mL	0.431 mL
Compound A : Sodium hydroxide (molar ratio)	1 : 1.06	1 : 1.06
Water for injection	total 1 mL	total 2 mL

Table 6

Items	Qualities of injectable composition immediately after production
Formulation 1	
Color of freeze-dried preparation	White
Dissolution state of preparation after being dissolved in physiological saline (2.5 mL)	Transparent and colorless
Foreign insoluble matter in preparation after being dissolved in physiological saline (2.5 mL)	Free of foreign insoluble matter
Particulate matter in preparation after being dissolved in physiological saline (2.5 mL)	Adapted to Japanese Pharmacopoeia 12
Content of Compound A	14.8 mg
Formulation 2	
Color of freeze-dried preparation	White
Dissolution state of preparation after being dissolved in physiological saline (5 mL)	Transparent and colorless
Foreign insoluble matter in preparation after being dissolved in physiological saline (5 mL)	Free of foreign insoluble matter

EP 1 310 252 A1

Table 6 (continued)

	Items	Qualities of injectable composition immediately after production
5	Formulation 2	
	Particulate matter in preparation after being dissolved in physiological saline (5 mL)	Adapted to Japanese Pharmacopoeia 12
10	Content of Compound A	30.0 mg

Experimental Example 2

[0117] In accordance with the formulation 2 in Table 5, the compound A was quickly dissolved in 0.2 mol/L sodium hydroxide aqueous solution, and then mannitol, N-methylglucamine and a water for injection were added thereto to dissolve followed by sterile filtration with a filter (0.22 μm) made from Durapola (manufactured by Nihon Millipore Ltd.). The resultant preparation solution (2 mL) was filled into 17P vial and frozen to -40°C followed by lyophilization by elevating shelf temperature to 30°C with keeping a degree of vacuum in a drying oven at 13.3 Pa to produce freeze-dried injectable composition.

[0118] The stability of the resultant freeze-dried injectable composition was evaluated by standing the injectable composition at 40°C and 75%RH. The results are shown in Table 7.

[0119] As apparent from Table 7, the freeze-dried injectable composition of the formulation 2 in Table 5 is stable at 40°C and 70%RH for 6 months, and the qualities of the injectable composition are sufficient. Moreover, it is apparent that the freeze-dried injectable composition of the formulation 1 in Table 5 produced by being filled with a half-volume portion into vials is similarly stable.

EP 1 310 252 A1

Table 7

Items	Immediately after production	40°C, 3 months	40°C, 4 months	40°C, 6 months
Color of freeze-dried injectable composition	White	White	White	White
Dissolution state of injectable composition after being dissolved in physiological saline (5 mL) Foreign insoluble matter in injectable composition after being dissolved in physiological saline (5 mL)	Transparent and colorless None	Transparent and colorless None	Transparent and colorless None	Transparent and colorless None
Content of Compound A (residual ratio (%))	100.0%	99.6%	99.0%	98.9%

EP 1 310 252 A1

Experimental Example 3

[0120] In the case (1) where the freeze-dried injectable composition of the formulation 2 obtained in Experimental Example 1 was redissolved in a physiological saline (5 mL) followed by being diluted with a physiological saline (100 mL), and in the case (2) where the freeze-dried injectable composition was redissolved in 5% glucose solution (5 mL) followed by being diluted with 5% glucose solution (100 mL), the transitional stability of each injectable composition was evaluated under irradiation of a white-fluorescent light having 1000 lux. The results are shown in Table 8.

[0121] As apparent from Table 8, both injectable compositions (1) and (2) in the cases redissolved in a physiological saline and 5% glucose solution and further diluted with a physiological saline and 5% glucose solution, respectively, are stable for 8 hours, and the qualities of the injectable compositions are sufficient.

EP 1 310 252 A1

5
10
15
20
25
30
35
40
45
50

Table 8

Diluted with physiological saline		Diluted with 5% glucose solution	
0 hour	After 4 hours	0 hour	After 8 hours
Transparent	Transparent	Transparent	Transparent
Colorless	Colorless	Colorless	Colorless
pH	9.8	9.4	9.3
Content of Compound A (residual ratio (%))	100.0%	100.0%	98.5%

Experimental Example 4

[0122] In accordance with the formulation in Table 9, the compound A was dissolved in 0.2 mol/L sodium hydroxide aqueous solution (1.06 mol of sodium hydroxide relative to 1 mol of the compound A), and then mannitol, N-methylglucamine and a water for injection were added thereto to dissolve followed by sterile filtration with a filter (0.22 μm) made from Durapola (manufactured by Nihon Millipore Ltd.). Each of the resultant preparation solutions (2 mL) was

EP 1 310 252 A1

filled into a vial followed by lyophilization to produce a freeze-dried injectable composition. The outer appearance of each freeze-dried injectable composition and the state of each freeze-dried injectable composition when redissolved in a physiological saline (5 mL) are shown in Table 10.

[0123] As apparent from Table 10, the injectable compositions obtained by adding 30 to 100 mg of mannitol and 10 to 20 mg of N-methylglucamine relative to 30 mg of the compound A are particularly excellent injectable compositions.

Table 9

	Formulation					
	1	2	3	4	5	6
Compound A (mg)	30					
0.2 mol/L sodium hydroxide (mL)	0.431					
Mannitol (mg)	0	30	60	60	100	100
N-methylglucamine (mg)	10	10	10	20	10	20
Water for injection (total; mL)				2		

EP 1 310 252 A1

5
10
15
20
25
30
35
40
45
50
55

Table 10

Formulation						
1	2	3	4	5	6	
Appearance*)	Bad	Good	Good	Good	Good	Good
Dissolution state	Opaque and colorless	Transparent and colorless	Transparent and colorless	Transparent and colorless	Transparent and colorless	Transparent and colorless

*) Appearance: the term "bad" means that the injectable composition was inappropriate for an injectable composition, and the term "good" means that the injectable composition was appropriate for an injectable composition.

EP 1 310 252 A1

Experimental Example 5

[0124] N-methylglucamine solutions (100 mL) in concentrations of 0.1% and 1.0% were prepared. The pH of each preparation solution was adjusted to about 11 with the use of 1 mol/L sodium hydroxide. With stirring each preparation solution, to 0.1% N-methylglucamine solution and 1.0% N-methylglucamine solution was added hydrochloric acid (1 mol/L) in increments of 0.1 mL and 0.5 mL, respectively. The pH of each preparation solution was evaluated. The results are shown in Fig. 1.

[0125] As apparent from Fig. 1, both 0.1% and 1.0% N-methylglucamine solutions have buffer capacities at least under the pH of about 9 to 11. Further, it is apparent that 1% N-methylglucamine solution has a buffer capacity in a broad range of pH of about 8 to 11.


Experimental Example 6

[0126] The freeze-dried injectable composition obtained in Experimental Example 2 was redissolved in 5 mL of a physiological saline and it was confirmed that pH of the resultant solution was about 11. Moreover, 0.1 mol/L sodium hydroxide was added to 5 mL of the same physiological saline as one used for redissolving to adjust pH of the mixture to about 11. With stirring each preparation solution, 0.1 mol/L hydrochloric acid was added thereto dropwise, and the pH of the redissolved solution was evaluated. The results are shown in Fig. 2.

[0127] As apparent from Fig. 2, the freeze-dried injectable composition containing N-methylglucamine in Experimental Example 2 has a buffer capacity in the range of pH of about 9 to 11. It is apparent that according to the injectable composition of the present invention, the decline of pH can be decreased in the range of pH of about 9 to 11, and the deterioration in quality thereof can be prevented.

Claims

1. An injectable composition, comprising a compound represented by the formula (I):



wherein a ring A represents a benzene ring which may have a substituent,

R¹ represents a hydrogen atom, an alkyl group which may have a substituent, an acyl group or an acyloxy group,

R², R³ and R⁴ are same or different, each representing a hydrogen atom, an alkyl group which may have a substituent, an alkoxy group which may have a substituent, or an amino group which may have a substituent,


X represents a nitrogen atom or CH, and

Y represents a nitrogen atom or CH, or a salt thereof

and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former.

2. A salt according to Claim 1, wherein, in the formula (I), the ring A represents a benzene ring which may have substituent(s) selected from the group consisting of a halogen atom, a C₁₋₄alkyl group which may be halogenated, a C₁₋₄alkoxy group which may be halogenated and a 5- or 6-membered heterocyclic group; R¹ represents a hydrogen atom; R² represents a C₁₋₆alkyl group, a C₁₋₆alkoxy group, a C₁₋₆alkoxy-C₁₋₆alkoxy group or a di-C₁₋₆alkylamino group; R³ represents a hydrogen atom, a C₁₋₆alkoxy-C₁₋₆alkoxy group, or a C₁₋₆alkoxy group which may be halogenated; R⁴ represents a hydrogen atom or a C₁₋₆alkyl group; and X and Y each represents a nitrogen atom.
3. An injectable composition according to Claim 1, wherein the compound represented by the formula (I) is a compound represented by the following formula (Ia):

EP 1 310 252 A1



wherein R¹ represents a hydrogen atom; R² represents a C₁₋₃alkyl group or a C₁₋₃alkoxy group; R³ represents a C₁₋₃alkoxy group which may be halogenated or may be substituted with a C₁₋₃alkoxy group; R⁴ represents a hydrogen atom or a C₁₋₃alkyl group; and R⁵ represents a hydrogen atom, a C₁₋₃alkoxy group which may be halogenated, or a pyrrolyl group.

4. An injectable composition according to Claim 3, wherein, in the formula (Ia), R¹ represents a hydrogen atom; R² represents a C₁₋₃alkyl group; R³ represents a C₁₋₃alkoxy group which may be halogenated; R⁴ represents a hydrogen atom; and R⁵ represents a hydrogen atom or a C₁₋₃alkoxy group which may be halogenated.
5. An injectable composition according to Claim 1, which is dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent.
6. An injectable composition according to Claim 1, wherein the strong alkali is an alkali metal compound.
7. An injectable composition according to Claim 1, wherein the strong alkali is sodium hydroxide.
8. An injectable composition according to Claim 1, wherein the equivalent ratio of the strong alkali relative to 1 mol of the compound represented by the formula (I) or a salt thereof is 0.90 to 1.10.
9. An injectable composition according to Claim 1, the solution of which has a pH of 10.4 to 12.0 in the case where the injectable composition is dissolved with the use of a physiological saline, or a distilled water for injection in a proportion of 2.5 ml relative to 15 mg of the compound represented by the formula (I) or a salt thereof.
10. An injectable composition according to Claim 1, the solution of which has an osmotic pressure ratio of about 0.3 to 5 against a physiological saline in the case where the injectable composition is dissolved with the use of the physiological saline in a proportion of 2.5 ml relative to 15 mg of the compound represented by the formula (I) or a salt thereof.
11. An injectable composition according to Claim 1, which is a freeze-dried preparation.
12. An injectable composition according to Claim 1, which further comprises N-methylglucamine.
13. An injectable composition according to Claim 12, wherein the amount of N-methylglucamine is about 0.1 to 1 mg relative to 1 mg of the compound represented by the formula (I) or a salt thereof.
14. An injectable composition according to Claim 1, which further comprises a saccharide.
15. An injectable composition according to Claim 14, wherein the saccharide is a sugar alcohol.
16. An injectable composition according to Claim 14, wherein the saccharide is mannitol.
17. An injectable composition according to Claim 14, wherein the amount of the saccharide is about 0.1 to 20 mg relative to 1 mg of the compound represented by the formula (I) or a salt thereof.
18. An injectable composition according to Claim 1, which comprises the compound represented by the formula (I) or a salt thereof and is dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent, and which further comprises about 0.1 to 0.8 mg of N-methylglucamine and about 1 to 10 mg of a sugar alcohol relative to 1 mg of the compound represented by the formula (I) or a salt thereof.

EP 1 310 252 A1

19. An injectable composition according to Claim 1, which comprises the compound represented by the formula (I) or a salt thereof and is dissolvable in or dilutive with a solvent substantially free from a nonaqueous solvent, and which further comprises about 4 to 6 mg of N-methylglucamine, about 25 to 35 mg of mannitol and about 1.5 to 1.8 mg of a sodium hydroxide relative to 15 mg of the compound represented by the formula (I) or a salt thereof.
20. An injectable composition according to Claim 1, which comprises 30 mg of the compound represented by the formula (I) or a salt thereof, 3.45 mg of a sodium hydroxide, 10 mg of N-methylglucamine and 60 mg of mannitol.
21. An injectable composition according to Claim 1, which comprises 15 mg of the compound represented by the formula (I) or a salt thereof, 1.73 mg of a sodium hydroxide, 5 mg of N-methylglucamine and 30 mg of mannitol.
22. A freeze-dried preparation which is dissolvable in at least one liquid selected from waters for injection and infusion solutions, comprises a compound represented by the formula (I) defined in Claim 1 or a salt thereof and an alkali metal hydroxide in a molar ratio of 1 : 0.90 to 1.10, and further comprises about 0.1 to 0.8 mg of N-methylglucamine and about 1 to 10 mg of a sugar alcohol relative to 1 mg of the compound represented by the formula (I) or a salt thereof.
23. A process for producing an injectable composition which comprises dissolving a compound represented by the formula (I) defined in Claim 1 or a salt thereof in an aqueous solution of a strong alkali, wherein the concentration of the aqueous solution of the strong alkali is about 0.15 to 0.25 equivalent/L, and the amount of the aqueous solution of the strong alkali is about 1 equivalent relative to 1 mol of the compound represented by the formula (I) or the salt thereof.
24. A process according to Claim 23, wherein the aqueous solution of the strong alkali is an aqueous solution of sodium hydroxide.
25. An injectable composition, which is obtainable by a production process of Claim 23.
26. A method for improving a relief of a pain or dolor and local irritation by an injectable composition, which comprises preparing the injectable composition with the use of a compound represented by the formula (I) defined in Claim 1 or a salt thereof and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former without a nonaqueous solvent.
27. A method for improving a solubility of a freeze-dried preparation in at least one liquid selected waters for injection and infusion solutions, without using a nonaqueous solvent, which comprises preparing the freeze-dried preparation with the use of a compound represented by the formula (I) defined in Claim 1 or a salt thereof and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former.
28. A method for preventing or treating digestive ulcer, gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer, gastric MALT lymphoma, upper gastrointestinal hemorrhage, ulcer caused by a nonsteroidal anti-inflammatory agent, hyperacidity and ulcer due to postoperative stress, or disease due to Helicobacter pylori, which comprises administering an injectable composition recited in Claim 1 to a human being.
29. Use of an injectable composition comprising a compound represented by the formula (I) defined in Claim 1 or a salt thereof and a strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former for preventing or treating digestive ulcer, gastritis, reflux esophagitis, NUD (Non-Ulcer Dyspepsia), gastric cancer, gastric MALT lymphoma, upper gastrointestinal hemorrhage, ulcer caused by a nonsteroidal anti-inflammatory agent, hyperacidity and ulcer due to postoperative stress, or disease due to Helicobacter pylori.
30. Use of a strong alkali for producing an injectable composition comprising a compound represented by the formula (I) defined in Claim 1 or a salt thereof and the strong alkali in a proportion of about 1 equivalent of the latter relative to 1 mol of the former.
31. Use of a strong alkali according to Claim 30, wherein the injectable composition is a freeze-dried preparation.

EP 1 310 252 A1

Fig. 1





Fig. 2



EP 1 310 252 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/07075

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.⁷ A61K31/4439, 31/4184, 31/404, 9/08, 9/19, A61K47/02, 47/26,
A61P1/04, 31/04, 35/00, C07D401/12, 235/28, 209/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl.⁷ A61K31/4439, 31/4184, 31/404, 9/08, 9/19, A61K47/02, 47/26,
A61P1/04, 31/04, 35/00, C07D401/12, 235/28, 209/30

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Jitsuyo Shinan Koho 1926-1996 Toroku Jitsuyo Shinan Koho 1994-2001
Kokai Jitsuyo Shinan Koho 1971-2001 Jitsuyo Shinan Toroku Koho 1996-2001

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS (STN), REGISTRY (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/2141 A1 (Fujisawa Pharmaceutical Co., Ltd.), 03 February, 1994 (03.02.94), Claims; working example 1	1-11, 23-27, 30-31 12-22
Y	& JP 6-92853 A (Claims; working example 1), & EP 652751 A1 & HU 71900 A2 & AT 144421 E & BS 2093445 T3 & CZ 284249 B6 & SK 279554 B6 & RU 2126252 C1 & NO 9500178 A & US 5580491 A & FI 9500379 A & CA 2140347 A & NZ 254237 A & DK 652751 T & AU 4583893 A & DE 69305642 C & GR 3021937 T & HK 52397 A & SG 52479 A & KR 258423 B	
X	WO 99/00380 A1 (Astra Aktiebolag), 07 January, 1999 (07.01.99), page 6, lines 22 to 27; working example 3	1-11, 23-25, 30-31 12-22
Y	& JP 2001-508805 A (page 9, lines 11 to 16; working examples 1, 3), & SE 9702483 A & AU 9881353 A1	26-27

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search
03 December, 2001 (03.12.01)

Date of mailing of the international search report
11 December, 2001 (11.12.01)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

EP 1 310 252 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/07075

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& EP 991641 A1 & BR 9810483 A1 & ZA 9805317 A & US 6207188 A & NO 9906440 A	
X	EP 382489 A2 (Takeda Chemical Industries, Ltd.), 16 August, 1990 (16.08.90),	1-4, 6-13, 23-25, 30-31
Y	Claims; working example 2	14-17, 20-21
A	& JP 3-173817 A (Claims; working example 2), & BS 2066120 T3 & CA 2009741 A & CA 2009741 C & NO 9000639 A & US 5013743 A & FI 940951 A & AT 114114 E & DE 69014141 C & DK 382489 T & GR 301973 T	5, 18-19, 22, 26-27
Y	JP 8-283158 A (Takeda Chemical Industries, Ltd.), 29 October, 1996 (29.10.96), Claims; working example 4 (Family: none)	12-22
Y	EP 649655 A1 (Takeda Chemical Industries, Ltd.), 26 April, 1995 (26.04.95), Claims; working examples 1 to 6 & JP 7-157440 A (Claims; working examples 1 to 6), & CA 2118195 A & FI 9404832 A & NO 9403888 A & BR 9404114 A & HU 70565 A2 & US 5536735 A	14-22
Y	WO 97/17064 A1 (Sanofi), 15 May, 1997 (15.05.97), Claims 1, 4, 6, 8; page 2, lines 26 to 34; page 9, line 36 & JP 11-507945 A1 (Claims 1, 4, 6, 8; page 7, line 23 to page 8, line 1; page 15, line 12), & FR 2740686 A1 & CA 2234140 A & AU 9674990 A1 & EP 858325 A1 & CN 1203527 A & BR 9611367 A & CZ 287178 B6 & IL 124214 A1 & NO 9801967 A & US 6284277 A & PL 326451 A & SK 52598 A & NZ 321616 A & HU 9900016 A	14-22

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

EP 1 310 252 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/07075

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28-29
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 28 and 29 pertains to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2) (a) (1) of the PCT and Rule 39.1 (iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)